Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry-Reference-Cited by-同舟云学术

Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry

Published:2022-08-30 Issue: Volume: Page:
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Valcarcel Sena,Gallego Javier,Jimenez-Fonseca Paula,Diez Marc,de Castro Eva Martínez,Hernandez Raquel,Arrazubi Virginia,Custodio Ana,Cano Juana María,Montes Ana Fernández,Macias Ismael,Visa Laura,Calvo Aitana,Tocino Rosario Vidal,Lago Nieves Martínez,Limón María Luisa,Granja Mónica,Gil Mireia,Pimentel Paola,Macia-Rivas Lola,Pérez Carolina Hernández,Mangas Montserrat,Carnicero Alfonso Martín,Cerdà Paula,Gonzalez Lucía Gomez,Navalon Francisco Garcia,Rambla Mª Dolores Mediano,Richard Marta Martin,Carmona-Bayonas Alberto

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00432-022-04294-6.pdf

Reference55 articles.

1. Alvarez-Manceñido F, Jimenez-Fonseca P, Carmona-Bayonas A et al (2021) Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry. Gastric Cancer 24:926–936. https://doi.org/10.1007/s10120-021-01169-6

2. Bang Y-J, van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697. https://doi.org/10.1016/S0140-6736(10)61121-X

3. Bartsch R, Wenzel C, Altorjai G et al (2007) Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 25:3853–3858. https://doi.org/10.1200/JCO.2007.11.9776

4. Bürkner P-C (2017) brms: an R package for bayesian multilevel models using Stan. J Stat Softw. https://doi.org/10.18637/jss.v080.i01

5. Carmona-Bayonas A, Jiménez-Fonseca P, Lorenzo MLS et al (2016) On the effect of triplet or doublet chemotherapy in advanced gastric cancer: results from a national cancer registry. J Natl Compr Canc Netw 14:1379–1388. https://doi.org/10.6004/jnccn.2016.0148

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Surrogate endpoints in phase III randomized trials of advanced gastroesophageal cancer: A systematic review and meta-analysis;Critical Reviews in Oncology/Hematology;2024-09